Cassava Sciences, Inc. (NASDAQ:SAVA) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET
Company Participants
Richard Barry - Executive Chairman of the Board
James Kupiec - Chief Medical Officer
Eric Schoen - Chief Financial Officer
Christopher Cook - Senior Vice President and General Counsel
Conference Call Participants
Soumit Roy - Jones Trading Institutional Services LLC
Vernon Bernardino - H.C. Wainwright
Elemer Piros - Rodman and Renshaw
Operator
Welcome to Cassava Sciences Reports for the Second Quarter 2024. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this webcast is being recorded.
During this call and the question-and-answer session afterwards, representatives of Cassava Sciences may make what are known as forward-looking statements. A forward-looking statement is one of that is not a historical fact. Forward-looking statements are not guarantees and they involve risks, uncertainties, and assumptions. Such statements represent current expectations or beliefs concerning future events or future performance.
Forward-looking statements are predictions only based upon information currently available to the Company. Actual events or results could defer materially from those made in any forward-looking statements due to a number of factors, risks and uncertainties. Please refer to Cassava Sciences' recent filings with this SEC, including Form 10-K for a description of the factors that could cause the events or results to defer materially from those made in forward-looking statements.
Importantly, this conference call contains time sensitive information that is accurate only as of the date of the live webcast, the 8th of August, 2024. Except as required by law, the Company undertakes no obligation to revise or update any forward-looking statements to reflect events and circumstances after the date of this webcast.
It is now my pleasure to turn today's meeting over to Rick Barry, Executive Chairman of the Board of Directors. The floor is yours.
Richard Barry
Thank you, Judith. Good morning and thank you for joining us. With me today are three key members of the Cassava team. Dr. Jim Kupiec, our Chief Medical Officer; Eric Schoen, Cassava's Chief Financial Officer; and Chris Cook, our General Counsel and Internal Swiss Army knife. You will be meeting other talented players on the team in the future.
We have a lot of material to cover this morning. So I'll get right to it. By now, you have hopefully seen the press release that we put out this morning that discusses some of our progress during the second quarter. Specifically, we highlighted the progress in our Phase III trials. The execution of these trials has been impressive. We expect our last patient/last visit in our ReTHINK trial in early Q4 and a topline read out of the data by year-end.